Savicell Diagnostics

Blood Test for Early Cancer Detection

Health Tech & Life Sciences
Active
Pre-Funding Haifa Founded 2012
Total raised
Stage
Pre-Funding
Founded
2012
Headcount
8
HQ
Haifa
Sector
Health Tech & Life Sciences

About

Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, with a focus on cancer. The Well-Shield technology is designed to detect and interpret differential metabolic responses that can indicate disease intrusion and cell malformation, including cancer.

The company aspires to improve adherence to routine medical screenings through the use of patient-friendly blood tests. Savicell Diagnostics is a majority-owned subsidiary of Savicell Corporation, a Nevada-based corporation.

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Savicell Diagnostics' primary product?
Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, with a focus on cancer.
When was Savicell Diagnostics founded?
Savicell Diagnostics was founded in April 2012.
What is the current employee count for Savicell Diagnostics?
Savicell Diagnostics currently has 8 employees.
What is the current funding stage of Savicell Diagnostics?
Savicell Diagnostics is currently in the Pre-Funding stage.
What was a significant collaboration for Savicell Diagnostics in August 2021?
In August 2021, Orgenesis announced a collaboration with Savicell Diagnostics on its ImmunoBiopsy platform.
What type of technology does Savicell Diagnostics utilize for its Well-Shield platform?
The Well-Shield technology is designed to detect and interpret differential metabolic responses that can indicate disease intrusion and cell malformation, including cancer.
Where is Savicell Diagnostics headquartered?
Savicell Diagnostics is headquartered in Haifa, Israel.
What was reported about Savicell Diagnostics' blood test for lung cancer in July 2019?
In July 2019, news sources reported on Savicell Diagnostics' revolutionary blood test designed to detect stage 1 lung cancer.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & Screening
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

diagnosticsmedical-technologiesblood-testbiotechnologycancerearly-detectionclinical-dataoncologyclinicshospitalsacademialaboratorieshealthcare-providersminimally-invasivepulmonary